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Methods: We analysed data on drug resistance among new and
previously treated TB cases reported by countries to WHO up to
2012. Data are collected in surveys of a representative sample of
TB patients or from surveillance systems in which diagnostic drug
susceptibility testing is routine practice, and quality-assured by the
Supranational TB Reference Laboratory Network.
Findings: In 1994-2012, surveillance data on MDR-TB were
reported from136 countriesworldwide. Global proportions of new
and previously treated TB cases with MDR-TB were 3.6% (95% CI:
2.1-5.1) and 20.2% (95% CI: 13.3-27.2), respectively. The highest
proportions are found in countries of the former Soviet Union
(FSU), where in several countries more than 20% of new cases and
more than 50% of previously treated cases haveMDR-TB. Estimated
MDR-TB incidence rates (MDR-TB cases per 100,000 population)
are highest in FSU countries and in southern Africa. Extensively
drug-resistant TB (XDR-TB) has been reported by 92 countries.
On average, an estimated 9.6% (95% CI: 8.1%–11%) of MDR-TB
cases have XDR-TB. A signiﬁcant positive association between
HIV and MDR-TB has been shown in 12 countries. Between 1994
and 2012, data on time trends in drug resistance were available
from 88 countries and 10 territories worldwide for a total of 870
country-year data points. Rates of MDR-TB in the general popula-
tion increased in Botswana, United Kingdom, and in Oblasts of the
Russian Federation and declined in Latvia, Estonia, and the United
States of America.
Conclusion: Better data from continuous surveillance or sur-
veys are required, especially from Africa and India. Trends in
MDR-TB are still unclear in most settings. Surveys should be
repeatedmore frequently usingmolecular technologies tomonitor
the MDR-TB epidemic more effectively.
http://dx.doi.org/10.1016/j.ijid.2014.03.446
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New developments in rapid diagnostics for drug
resistant tuberculosis
M.P. Nicol
University of Cape Town, Cape Town, South Africa
There has been considerable recent advance in the develop-
ment of rapid tests for diagnosis of drug-resistant tuberculosis.
These advances are primarily due to a fundamental change from
a phenotypic to genotypic approach to testing. The two most com-
monly used genotypic tests for resistance to ﬁrst-line drugs are
line probe assays and Xpert MTB/RIF. Line probe assays detect
resistance to rifampicin and isoniazid in cultured isolates of M.
tuberculosis, as well as directly in smear-positive (and possibly
smear-negative) sputum specimens. These assays are highly sensi-
tive and speciﬁc for detection of resistance to rifampicin, but less
sensitive for detection of isoniazid resistance. Xpert MTB/RIF may
be used for immediate, direct detection of rifampicin resistant M.
tuberculosis in sputum specimens, including themajority of smear-
negative specimens. Early reports showed high sensitivity and
speciﬁcity for detection of resistance, however the predictive value
of this assay for resistance may be impaired in patients at low risk
for rifampicin-resistant tuberculosis. More recent assay versions
appear to have substantially improved speciﬁcity. After rifampicin-
resistant tuberculosis is detected by one of these initial tests, there
is a need to rapidly determine susceptibility to second-line drugs.
At present, there are no highly accurate genotypic tests for predic-
tion of resistance, and prolonged culture-based phenotypic testing
is required. A line probe assay for detection of resistance to ﬂuoro-
quinolones, injectables and ethambutol in smear-positive sputum
specimens is available; however there is geographic variation in
the distribution of different resistance mutations and lack of pre-
dictable cross-resistance to different drugs in a class. This assay
is therefore speciﬁc for detection of XDR-TB, but lacks sensitiv-
ity. New developments in the ﬁeld include highly multiplexed
real-time PCR tests for detection of resistance and the use of
whole genome sequencing for broad detection of resistance muta-
tions. The ﬁeld is, at present, limited by incomplete understanding
of genotype-phenotype relationships and by the need for robust
bioinformatics pipelines to facilitate sequence analysis and infer
resistance patterns from sequence data.
http://dx.doi.org/10.1016/j.ijid.2014.03.447
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Newer and novel insights into the pathogenesis
and treatment of drug-resistant tuberculosis
K. Dheda
University of Cape Town, Cape Town, South Africa
Drug-resistant tuberculosis (MDR and XDR-TB) is a burgeoning
global health crisis with a high mortality irrespective of HIV-
status. In South Africa, despite comprising less than 3% of the total
caseload, DR-TB consumes almost half of the total national TBman-
agement budget - this is unsustainable and threatens to destabilise
national TB programs. MDR-TB has been eclipsed by the spectre
of resistance beyond XDR-TB (totally drug-resistant TB [TDR-TB]
and XXDR-TB) i.e. resistance to all or nearly all conventionally used
ﬁrst and second line TB drugs. Given the limited availability of
new drugs in a TB endemic setting, their preferred use in newer
ﬁrst line regimens, the ﬁnite nature of the drug pipeline, and the
likely rapid evolution of drug-resistance, alternative or adjunctive
therapeutic options are urgently needed. The traditional view is
that drug-resistance arises because of non-adherence or pharma-
cokinetic mismatch resulting in killing of susceptible populations
but overgrowth of resistant ones. However, several new con-
cepts have challenged this understanding, including within person
PK variability, induction of efﬂux pumps, immunopathology-
driven intrapulmonary drug gradients, pathogen-related factors,
including compensatory mutations which impact ﬁtness cost and
physiological pathways, and recognition of “super-spreaders” that
transmit the majority of disease. Several new drugs have also
emerged for the potential treatment of drug-resistant TB. Those
already in clinical use or likely to be imminently available will be
brieﬂy discussed including bedaqualine, delamanid, and linezolid.
Finally, given the seriousmortality and limited therapeutic options
in highly resistant strains the utility of novel immunotherapeutic
approaches are brieﬂy discussed.
http://dx.doi.org/10.1016/j.ijid.2014.03.448
